New diagnostic and therapeutic advances in cardiovascular disease
1.- Preclinical and translational cardiovascular research:
Our work has been developed in the field of cardiovascular imaging technology applied to translational research, in coordination with basic scientists at the Hospital de La Princesa and the Centro Nacional de Investigaciones Cardiovasculares (CNIC, National Centre for Cardiovascular Research). In collaboration with basic scientists, we have contributed our vision of translational science and the application of cardiovascular imaging technology to preclinical and clinical research. Our collaborations include work on mouse and zebrafish models of myocardial regeneration, atherosclerosis, heart ageing, systolic, diastolic and diabetic heart failure, non-compacted cardiomyopathy, left ventricular hypertrophy, aortic aneurysm, aortic valve degeneration, annuloaortic ectasia, mitral insufficiency, coronary aneurysm, acute pulmonary hypertension, and chronic pulmonary hypertension. In many of these projects, our cardiovascular image analysis and clinical experience has led to the identification of possible clinical translation to human disease.
2.- Clinical Cardiovascular Research:
At Hospital de La Princesa our main line of research has focused on characterising the phenotype of patients with hypertrophic cardiomyopathy and its association with prognosis, by identifying new goals for cardiovascular imaging technology.
In collaboration with the CNIC, we have contributed to designing the following trials: Progression of early subclinical atherosclerosis (PESA) and Aragon Workers Health Study (AWHS). We are coordinating the imaging approach of these projects which involve two trials with large populations focused on early detection and progression of subclinical atherosclerosis in middle-aged adults.
We have consolidated our collaboration with basic scientists to translate their basic research to a clinical setting through the use of cardiovascular imaging technology. Our work on various mouse and zebrafish models is currently being developed, focusing on myocardial regeneration, atherosclerosis, heart ageing, systolic, diastolic and diabetic heart failure, non-compacted cardiomyopathy, left ventricular hypertrophy, aortic aneurysm, aortic valve degeneration, annuloaortic ectasia, mitral insufficiency, coronary aneurysm, acute pulmonary hypertension and chronic pulmonary hypertension.
In clinical research, Dr Jiménez Borreguero is currently coordinating a cardiomyopathy study at Hospital de La Princesa, and the image study as part of the PESA study at the CNIC until June 2019.
Luis Jesús Jiménez Borreguero
Hospital Universitario La Princesa
| Other team members.Hospital Universitario La Princesa:
Luxán G, Casanova JC, Martínez-Poveda B, Prados B, D'Amato G, MacGrogan D, Gonzalez-Rajal A, Dobarro D, Torroja C, Martinez F, Izquierdo-García JL, Fernández-Friera L, Sabater-Molina M, Kong YY, Pizarro G, Ibañez B, Medrano C, García-Pavía P, Gimeno JR, Monserrat L, Jiménez-Borreguero LJ, de la Pompa JL. Mutations in the NOTCH pathway regulator MIB1 cause left ventricular noncompaction cardiomyopathy. Nat. Med. 2013. 19: 193-201. FI: 28.054(Q1). PMID: 23314057. DOI: 10.1038/nm.3046.
Esteban, Vanesa, Mendez-Barbero, Nerea, Jesus Jimenez-Borreguero, Luis, Roque, Merce, Novensa, Laura, Belen Garcia-Redondo, Ana, Salaices, Mercedes, Vila, Luis, Arbones, Maria L., Campanero, Miguel R., Miguel Redondo, Juan. Regulator of calcineurin 1 mediates pathological vascular wall remodeling. J. Exp. Med. 2011. 208: 2125-2139. FI: 13.853(Q1). PMID: 21930771. DOI: 10.1084/jem.20110503.
Fernández-Ortiz A, Jiménez-Borreguero LJ, Peñalvo JL, Ordovás JM, Mocoroa A, Fernández-Friera L, Laclaustra M, García L, Molina J, Mendiguren JM, López-Melgar B, de Vega VM, Alonso-Farto JC, Guallar E, Sillesen H, Rudd JH, Fayad ZA, Ibañez B, Sanz G, Fuster V. The Progression and Early detection of Subclinical Atherosclerosis (PESA) study: Rationale and design. Am Heart J 2013. 166: 990-998. FI: 4.555(Q1). PMID: 24268213. DOI: 10.1016/j.ahj.2013.08.024.
Ibanez B, Macaya C, Sánchez-Brunete V, Pizarro G, Fernández-Friera L, Mateos A, Fernández-Ortiz A, García-Ruiz JM, García-Álvarez A, Iñiguez A, Jiménez-Borreguero J, López-Romero P, Fernández-Jiménez R, Goicolea J, Ruiz-Mateos B, Bastante T, Arias M, Iglesias-Vázquez JA, Rodriguez MD, Escalera N, Acebal C, Cabrera JA, Valenciano J, Pérez de Prado A, Fernández-Campos MJ, Casado I, García-Rubira JC, García-Prieto J, Sanz-Rosa D, Cuellas C, Hernández-Antolín R, Albarrán A, Fernández-Vázquez F, de la Torre-Hernández JM, Pocock S, Sanz G, Fuster V. Effect of Early Metoprolol on Infarct Size in ST-Segment-Elevation Myocardial Infarction Patients Undergoing Primary Percutaneous Coronary Intervention The Effect of Metoprolol in Cardioprotection During an Acute Myocardial Infarction (METOCARD-CNIC) Trial. Circulation 2013. 128: 1495-1503. FI: 14.948(Q1). PMID: 24002794. DOI: 10.1161/CIRCULATIONAHA.113.003653.